Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...
Divested assets to include Xiidra ®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface pain Deal consistent with Novartis focused strategy of ...
. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...
Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transaction includes enabling technology platforms and therapeutic ...
About Novartis in Cardiovascular Disease At Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We’re proud ...
Having elevated levels of lipoprotein (a), or Lp (a) for short, increases a person’s chances of having a cardiovascular event such as a stroke or a heart attack. It was after having two heart attacks ...
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...
The Novartis HIT team is composed of experienced technical subject matter experts. These informaticists specialize in patient-centered care and HIT optimization coordination. The HIT Team can offer ...
Bryan Laffitte has had a long career at Novartis in San Diego, California—with some twists and turns. After spending thirteen years at Novartis in a variety of roles, he explored opportunities in ...
One of the secrets to living a longer, better life is beating in our chests. An estimated 80% of cardiovascular disease (CVD) can be prevented with lifestyle changes and available tools, yet it ...
Acute myeloid leukemia (AML), the most common form of acute leukemia in adults, is a cancer of the blood and bone marrow. Prognosis and survival rate may depend on numerous factors.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results